Clinical Trial Update: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 evaluation of TAK-279 for moderate-to-severe plaque psoriasis; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• TAK-279

Snippet

Sponsor: Takeda | Conditions: Plaque Psoriasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING